Restricted accessResearch articleFirst published online 2015-9
Parent Perspectives on Psychotropic Medication Use and Interactions With Prescribing Health Care Providers Among Adolescents and Adults With an Autism Spectrum Disorder
Adolescents and young adults with an autism spectrum disorder (ASD) are often prescribed psychotropic medications to treat mental health and behavioral issues, and parents of these individuals play a crucial role in overseeing this care. Despite this, little is known about parents’ experiences managing and monitoring their child’s medication treatment, or their experience interacting with prescribing health care providers. To learn more about parents’ perspectives on psychotropic medication use in their adolescent or young adult with ASD, a focus group was conducted with seven mothers whose adolescent or adult child with ASD was prescribed one or more psychotropic medications. Results are summarized according to emergent themes including parent perception of child experience with medication, side effects, medication efficacy, medication monitoring, expertise issues, and service issues. Parents also provided medication recommendations, including a desire for health care providers with greater expertise in ASD, information on medication, and tools for medication monitoring.
BertelliM.MerliM. P.RossiM.LassiS.BiancoA.ColangeloJ. (2013). Quality of life in pharmacological intervention on autism spectrum disorders. Advances in Mental Health and Intellectual Disabilities, 7, 40–48.
4.
BorgheiniG. (2003). The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clinical Therapeutics, 25, 1578–1592.
5.
BroadstockM.DoughtyC.EgglestonM. (2007). Systematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorder. Autism, 11, 335–348.
6.
BromleyJ.HareD. J.DavisonK.EmersonE. (2004). Mothers supporting children with autistic spectrum disorders. Autism, 8, 409–423.
7.
CadmanT.EklundH.HowleyD.HaywardH.ClarkeH.FindonJ.. . . GlaserK. (2012). Caregiver burden as people with autism spectrum disorder and attention-deficit/hyperactivity disorder transition into adolescence and adulthood in the United Kingdom. Journal of the American Academy of Child & Adolescent Psychiatry, 51, 879–888.
8.
CarboneP. S.BehlD. D.AzorV.MurphyN. A. (2010). The medical home for children with autism spectrum disorders: Parent and pediatrician perspectives. Journal of Autism and Developmental Disorders, 40, 317–324.
9.
CharachA.SkybaA.CookL.AntleB. J. (2006). Using stimulant medication for children with ADHD: What do parents say? A brief report. Journal of the Canadian Academy of Child & Adolescent Psychiatry, 15, 75–83.
ColettiD. J.PappadopulosE.KatsiotasN. J.BerestA.JensenP. S.KafantarisV. (2012). Parent perspectives on the decision to initiate medication treatment of attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 22, 226–237.
12.
CouryD. L.AnagnostouE.Manning-CourtneyP.ReynoldsA.ColeL.McCoyR.. . . PerrinJ. M. (2012). Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics, 130, S69–S76.
13.
EsbensenA. J.GreenbergJ. S.SeltzerM. M.AmanM. G. (2009). A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. Journal of Autism and Developmental Disorders, 39, 1339–1349.
14.
GoeringP.BoydellK. M.PignatielloA. (2008). The relevance of qualitative research for clinical programs in psychiatry. Canadian Journal of Psychiatry, 53, 145–151.
15.
HarringtonJ. W.PatrickP. A.EdwardsK. S.BrandD. A. (2006). Parental beliefs about autism: Implications for the treating physician. Autism, 10, 452–462.
16.
KoegelL. K.KrasnoA. M.TarasH.KoegelR. L.FreaW. (2013). Is medication information for children with autism spectrum disorder monitored and coordinated across professionals? Findings from a teacher survey. School Mental Health, 5, 48–57.
17.
KoganM. D.StricklandB. B.BlumbergJ.SinghG. K.PerrinJ. M.van DyckP. C. (2008). A national profile of the health care experiences and family impact of autism spectrum disorder among children in the Unites States, 2005–2006. Pediatrics, 122, e1149–e1158.
18.
KonstantareasM.HomatidisS.CesaroniL. (1995). Brief report: Variables related to parental choice to medicate their autistic children. Journal of Autism and Developmental Disorders, 25, 443–452.
19.
LakeJ. K.BaloghR.LunskyY. (2012). Polypharmacy profiles and predictors among adults with autism spectrum disorders. Research in Autism Spectrum Disorders, 6, 1142–1149.
20.
LinL. (2010). Factors associated with caregiver burden and maternal pessimism in mothers of adolescents with an autism spectrum disorder in Taiwan. Occupational Therapy International, 18, 96–105.
21.
LiptakG. W.OrlandoM.YinglingJ. T.Theurer-KaufmanK. L.MalayD. P.TompkinsL. A.FlynnJ. R. (2006). Satisfaction with primary health care received by families of children with developmental disabilities. Journal of Pediatric Health Care, 4, 245–252.
22.
LoganS. L.NicholasJ. S.CarpenterL. A.KingL. B.Garrett-MayerE.CharlesJ. M. (2012). High prescription drug use and associated costs among Medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance network. Annals of Epidemiology, 22, 1–8.
23.
MackintoshV. H.Goin-KochelR. P.MyersB. J. (2012). “What do you like/dislike about the treatments you’re currently using?” A qualitative study of parents of children with autism spectrum disorders. Focus on Autism and Other Developmental Disabilities, 27, 51–60.
24.
MandellD. S.MoralesK. H.MarcusS. C.StahmerA. C.DoshiJ.PolskyD. E. (2008). Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121, 441–448.
25.
MatsonJ. L.DempseyT. (2008). Autism spectrum disorders: Pharmacotherapy for challenging behaviors. Journal of Developmental and Physical Disabilities, 20, 175–191.
26.
MatsonJ. L.HessJ. A. (2011). Psychotropic drug efficacy and side effects for persons with autism spectrum disorders. Research in Autism Spectrum Disorders, 5, 230–236.
27.
MengA.McConnellS. (2002). Decision-making in children with asthma and their parents. Journal of the American Academy of Nurse Practitioners, 14, 363–371.
28.
MireS. S.NowellK. P.KubiszynT.Goin-KochelR. P. (2013). Psychotropic medication use among children with autism spectrum disorders within the Simons Simplex Collection: Are core features of autism spectrum disorder related?Autism, 18, 933–942. doi:10.1177/1362361313498518
29.
MitchellD. B.Hauser-CramP. (2008). The well-being of mothers of adolescents with developmental disabilities in relation to medical care utilization and satisfaction with health care. Research in Developmental Disabilities, 29, 97–112.
30.
MorganD. L. (1997). Focus groups as qualitative research (2nd ed.). Thousand Oaks, CA: SAGE.
31.
MoyalW. N.LordC.WalkupJ. T. (2014). Quality of life in children and adolescents with autism spectrum disorders: What is known about the effects of pharmacotherapy?Pediatric Drugs, 16, 123–128.
32.
MyersS. M. (2007). The status of pharmacotherapy for autism spectrum disorders. Expert Opinion on Pharmacotherapy, 8, 1579–1603.
33.
MyersS. M.Plauche JohnsonC. (2007). Management of children with autism spectrum disorders. Pediatrics, 120, 1162–1182.
34.
OwleyT. (2002). The pharmacological treatment of autistic spectrum disorders. CNS Spectrums, 7, 663–669.
35.
RhoadesR. A.ScarpaA.SalleyB. (2007). The importance of physician knowledge of autism spectrum disorder: Results of a parent survey. BMC Pediatrics, 7, 1–10.
36.
RomanB. (2009). Patients’ attitudes towards generic substitution of oral atypical antipsychotics. CNS Drugs, 23, 693–701.
37.
RosenthalJ.KongB.JacobsL.KatzmanM. (2008). Did a switch to a generic antidepressant cause relapse?Journal of Family Practice, 57, 109–114.
38.
SchallC. (2002). A consumer’s guide to monitoring psychotropic medication for individuals with autism spectrum disorders. Focus on Autism and Other Developmental Disabilities, 17, 229–235.
39.
SpencerD.MarshallJ.PostB.KulakodluM.NewschafferC.DennenT.. . . JainA. (2013). Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics, 132, 833–840.
40.
SwiezyN. B.SummersJ. (1996). Parents’ perceptions of the use of medication with children who are autistic. Journal of Developmental and Physical Disabilities, 8, 407–413.
41.
TaylorS. J.BogdanR. (1998). Introduction to qualitative research methods: A guidebook and resource (3rd ed.). New York, NY: John Wiley & Sons.
42.
TsakanikosE.CostelloH.HoltG.BourasN.SturmeyP.NewtonT. (2006). Psychopathology in adults with autism and intellectual disability. Journal of Autism and Developmental Disorders, 36, 1123–1129.
43.
Van AmeringenM.ManciniC.PattersonB.BennettM. (2007). Symptom relapse following switch from Celexa to generic citalopram: An anxiety disorders case series. Journal of Psychopharmacology, 21, 472–476.
44.
WilliamsonE. D.MartinA. (2012). Psychotropic medications in autism: Practical considerations for parents. Journal of Autism and Developmental Disorders, 42, 1249–1255.
